International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.

Slides:



Advertisements
Similar presentations
17 September 2007ISO TC215 WG6 Brisbane1 Identification of Medicinal Products & Pharmacovigilance Task Forces.
Advertisements

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
APEC Regulatory Harmonization Steering Committee (RHSC) Institute of Medicine Workshop International Regulatory Harmonization Amid Globalization of Biomedical.
Breakout C Pharmaceutical Quality System (PQS)
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
11 th International Symposium Loss Prevention and Process Safety Promotion in the Process Industries 1 OECD Workshop on Sharing Experience in the Training.
A Case Study in the Value of Harmonisation Yoshikazu HAYASHI Deputy Director Evaluation and Licensing Division Pharmaceutical & Food Safety Bureau Ministry.
History and Background to the HACCP System
ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Manufacturing Implementation and the Pharmaceutical Quality System
Presented by: Karen Ginsbury For IFF, Denmark March 2012.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
Case Study.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
1 OECD Work on the Safety of Manufactured Nanomaterials Environment, Health and Safety Division Environment Directorate OECD.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Delivering a Modern Effective Pharmaceutical Quality System
EFSA MANAGEMENT PLAN 2008 The Management Plan
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Prequalification programme: Priority essential.
IAEA International Atomic Energy Agency Overview International Project on Innovative Nuclear Reactors and Fuel Cycles (INPRO) Presented by Jon R. Phillips.
Justina A. Molzon, MS Pharm, JD
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Overview of ICH Procedures July 2015
On ICH Feb. 13, 2013 Toshi Tominaga Ph. D. Food and Drug Evaluation Center, Osaka City Univ. Hospital International Regulatory Harmonization Amid Globalization.
History prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
Bioequivalence and Bioavailability Working Group.
DETERMINATION OF RELATED SUBSTANCES & IMPURITIES IN DRUGS BY ICH GUIDE LINES BY M.PAUL RICHARDS.
*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.
Regulation of medicines and other health technologies. The future of regulation, where are we going? EMP TBS November 2014, Geneva Dr Lembit Rägo Head,
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Breakout D Quality Risk Management
10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.
Anthony Serracino Inglott Chairman of the Malta Medicines Authority
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.
Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.
ASEAN Cooperation on Standards and Conformance Background Participation of stakeholders in the ACCSQ activities ACCSQ structure Measures undertaken Progress.
ICH Quality Topics Update
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
GOVERNANCE MODELS OF OTHER NETWORKS: APEC AND IMDRF 7 TH PAN AMERICAN CONFERENCE ON DRUG REGULATORY HARMONIZATION 5-7 SEPTEMBER, 2013 OTTAWA.
VICH General Principles and current update of VICH Outreach Forum activity 1.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.
Implementation of PANDRH Guidelines NAFTA Region VI PANDRH Conference Brasilia, July 2-8, 2011 Justina Molzon -- US Food and Drug Administration Mike Ward.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.
Vision: Next Steps and Global Outreach Joan Wilmarth Blair Sr. Advisor, International Affairs Center for Biologics Evaluation and Research, FDA.
VICH General Principles and
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Michelle Limoli, Pharm.D.
Reflections on International Cooperation
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Fundamentals of Electronic Submissions and eCTD
The Benefits of VICH to Emerging Countries
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Presentation transcript:

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10 ICH Q-IWG Integrated Training Programme J.-L. Robert, Q-IWG Rapporteur

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 2 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Disclaimer The information within this presentation is based on the ICH Q-IWG members expertise and experience, and represents the views of the ICH Q-IWG members for the purposes of a training workshop.

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 3 ICH Q-IWG Integrated Training Programme © ICH, November 2010 ICH: 20 years process (1) Start in 1990 (Brussels) Objective of ICH: Technical and scientific harmonisation between Japan, Europe and USA. Scope: New chemical entities and biotechnology derived products Sponsors: - Regulators: EU, FDA, MHLW - Industry: EFPIA, JPMA, PhRMA Observers: - EFTA, Health Canada, WHO Steering Committee

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 4 ICH Q-IWG Integrated Training Programme © ICH, November 2010 ICH: 20 years process (2) 1990: Pharmacopoeial Discussion Group - EP, JP, USP, WHO 1997: Interested Parties: IGPA, WSMI 1999: Global Cooperation Group RHIs: APEC, ASEAN, GCC, PANDRH, GCG DRAs: Australia, Brazil, China, India, Russia, Singapore, South Korea : DoH: Chinese Taipeh 2003: Quality New Paradigm 2006: Biotech Industry 2010: ICH Training: Implementation Q8, Q9, Q10

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 5 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Achieved so far (1) Areas - Quality, Safety, Efficacy - Multidisciplinary areas, MedDRA, e-submission,….. Initial ICH Quality topics - Scientific/technical guidelines mostly: Stability, Method Validation, Impurities, Specifications, Q5 series (Biological) - System oriented: GMP for APIs - Structure: Common Technical Document

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 6 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Quality: A New Paradigm Develop a harmonised pharmaceutical quality system applicable across the lifecycle of the product emphasizing an integrated approach to quality risk management and science - Q8:Pharmaceutical Development - Q8 (R2):Pharmaceutical Development Revision - Q9: Quality Risk Management - Q10: Pharmaceutical Quality System - Q11: Development and Manufacture of Drug Substances (chemical/biological entities): in progress (Brussels July 2003)

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 7 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Quality: A New Paradigm Main message Science is no longer isolated; it is living across the lifecycle of the product/process within a Quality Management System

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 8 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Quality: A New Paradigm The new paradigm emphasize: 1. Quality must be mainly built in and it will not only improve by additional testing and inspection 2. Better utilization of modern science throughout product lifecycle 3. QRM is a key enabler throughout product lifecycle 4. Robust PQS, with appropriate knowledge management, assures quality throughout product life cycle 5. An integrated approach to development, manufacturing and quality for both industry and regulators

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 9 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Implementation WG on Q8, Q9, Q10 Task of IWG Q8, Q9, Q10: - “….due primarily to departure from the traditional approaches to quality guidance, proper implementation of these concepts is provided by bringing clarity, further explanation and removing ambiguities and uncertainties”. - Technical issues & related documentation: - Additional implementation issues: influence on existing ICH guidelines; - Communication and training Unique training programme for industry and regulators (assessors and inspectors) in the three regions: - Tallinn June 2-4, Washington October 6-8, Tokyo October 25-27, 2010

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 10 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Structure of Washington Training Plenary presentations - Lifecycle of a drug product - Development, Assessment, Manufacturing, Inspection Breakout sessions - Design Space - Control Strategy - Pharmaceutical Quality System - Quality Risk Management Conclusions and next steps

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 11 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Training on Implementation of Q8, Q9, Q10 Training based on a case study. Integrated implementation of Q8, Q9, Q10 and application to drug products and related operations Opportunity for open dialogue between Regulators and Industry. Feedback from the workshops will be used to further facilitate the understanding and implementation of ICH Q8, Q9 and Q10.

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 12 ICH Q-IWG Integrated Training Programme © ICH, November 2010 Acknowledgement This presentation has been developed by members of the ICH Quality Implementation Working Group (Q-IWG) Jean-Louis Robert (rapporteur) Diana Amador-Toro Robert G. Baum Nicholas Cappuccino David Cockburn Georges France Richard L. Friedman Nigel Hamilton Hirotada Nagai Yukio Hiyama Fusashi Ishikawa Takao Kiyohara Urs Kopp Akira Kusai Yoshihiro Matsuda Motoaki Mitsuki Elaine Morefield Jacques Morénas Masatoshi Morisue Markus-Peter Müller Tamiji Nakanishi Moheb Nasr Kazuhiro Okochi Anthony Ridgway Rachael Roehrig Stephan Rönninger Swroop Sahota Hideki Sasaki Tetsuhito Takarada Shigeki Tamura Krishnan Tirunellai Mats Welin Jean M. Wyvratt A J van Zyl